Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate

Mesothelin (MSLN) has been a validated tumor-associated antigen target for several solid tumors for over a decade, making it an attractive option for therapeutic interventions. Novel antibodies with high affinity and better therapeutic properties are needed. In the current study, we have isolated an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Zehua, Chu, Xiaojie, Adams, Cynthia, Ilina, Tatiana V., Guerrero, Michel, Lin, Guowu, Chen, Chuan, Jelev, Dontcho, Ishima, Rieko, Li, Wei, Mellors, John W., Calero, Guillermo, Dimitrov, Dimiter S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522976/
https://www.ncbi.nlm.nih.gov/pubmed/37771390
http://dx.doi.org/10.1016/j.omto.2023.09.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522976/
https://www.ncbi.nlm.nih.gov/pubmed/37771390
http://dx.doi.org/10.1016/j.omto.2023.09.002

Ejemplares similares